Medarex, Inc. (MEDX)

[surf1944]

Company: Medarex(MEDX Quote) and Bristol-Myers Squibb(BMY Quote)

Drug/indication: ipilimumab for metastatic melanoma

Clinical trial event: phase III top-line results

Timing: end of 2009
More from Adam Feuerstein Biotech Stock Mailbag: Gleaming the CubistOculus Sidesteps FDA Rules With Wound CleanerCell Therapeutics: Deadline Nears for Debt Tender OfferVirus Forces Genzyme to Shut PlantNew RA Data Could Be Magic Pill for RigelBiotech Stock Mailbag: Good Stocks ExistHemispherx, in FDA Limbo, Seeks More CashBiotech Calendar: Key Clinical Trial DatesMicromet Cancer Drug Meets Goal; Shares RiseVanda Ripe for Picking, or Dead on the Vine? Market Activity Celgene Corporation| CELG UPGTX Incorporated| GTXI DOWNThe phase III study enrolls patients with previously untreated metastatic melanoma and treats them with a combination of ipilimumab plus the chemotherapy dacarbazine or dacarbazine plus placebo.

http://www.thestreet.com/story/10515986/3/biotech-calendar-more-key-clinical-trial-dates.html